FDA clears Current Health’s hospital-to-home wearable, combining analytics and passive vital sign tracking

senior
Current Health sees its device as a useful tool in value-based care, where decreasing hospital stays and avoiding readmissions will be a financial imperative. (Getty/noipornpan)

The FDA has cleared Current Health’s wearable tracker, designed to be taken home from the hospital after acute care to track a patient’s recovery in real time, with the ultimate goal of reducing readmissions.

The 510(k) clearance covers the Class II device and Current’s telehealth platform, which offers a dashboard for physicians, AI-based risk prediction and alerts, as well as secure video chat.

Meanwhile, the patient-facing side—delivered via a Current-issued tablet—includes medication reminders, automated symptom questionnaires and HIPAA-compliant text messaging.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Current’s passive device, worn on the upper arm, tracks vital signs with accuracy akin to the hardware found in an intensive care unit, according to the company. The device also received an FDA clearance earlier this year for its use within the hospital, to track movement, pulse, respiration rate, temperature and blood oxygen level.

Current Health's wearable. (Image: Current)

The company sees the device as a useful tool for hospitals, as the industry moves toward value-based care centered on patient outcomes—where decreasing lengths of stay and avoiding unnecessary hospitalizations will be a financial imperative. So far, Current has partnered with six health systems in the U.S., including Mount Sinai, along with several U.K. NHS Trusts.

“Our rapidly growing customer base indicates how focused health systems and home health agencies are on moving more healthcare from hospital to home,” Current CEO and co-founder Christopher McCann said in a statement.

“Today, Current is helping them do just that by monitoring patients’ health trajectories to enable earlier interventions, reduce the overall and growing cost of hospital readmissions and, more importantly, prevent avoidable deaths,” McCann added.

“But more fundamentally, we’re building a future where healthcare comes to us,” he said. “Patients don’t always know when to call their doctor. Current will.”

Suggested Articles

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.